Shots:
- The NMPA has approved the IND application for HBM7004 for the treatment of advanced solid tumors
- HBM7004 is a B7H4xCD3 bispecific antibody developed using HBM’s HBICE platform, designed to offer a differentiated cancer immunotherapy approach with potential efficacy & safety benefits
- In preclinical studies, HBM7004 induced B7H4-dependent intratumoral T-cell activation & demonstrated strong anti-tumor efficacy, high in vivo stability, & reduced systemic toxicity across multiple animal models. It also showed strong synergy with a B7H4x4-1BB bispecific antibody at low effector-to-target ratios
Ref: PRnewswire | Image: Harbour Biomed | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
